ARQT — Arcutis Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $3.38bn
- $3.26bn
- $376.07m
U.S. STOCKS ON THE MOVE-Biomerica, Netflix, SunPower
U.S. STOCKS ON THE MOVE-Occidental Petroleum, Scorpio Tankers, ZimVie
U.S. STOCKS ON THE MOVE-Micron, PGT Innovations, Adobe
U.S. STOCKS ON THE MOVE-GSK, Illumina, Nio
Arcutis jumps after US FDA approves skin disease drug
Brief: Huadong Medicine Says Unit, Arcutis Biotherapeutics' Drug Gets US FDA Approval
Brief: FDA Approves Arcutis’(Roflumilast) Topical Foam, 0.3% For The Treatment Of Seborrheic Dermatitis In Individuals Aged 9 Years And Older
Arcutis Biotherapeutics rises on FDA approval for drug to treat chronic skin disease
US FDA approves Arcutis' drug to treat chronic skin disease (updated)
US FDA approves Arcutis' drug to treat chronic skin disease
U.S. RESEARCH ROUNDUP- Pioneer Natural Resources,Oxford Industries, Nutrien
Arcutis Biotherapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Arcutis Biotherapeutics Q3 basic EPS USD -0.73
Arcutis Biotherapeutics Inc expected to post a loss of 86 cents a share - Earnings Preview
Brief: Arcutis Biotherapeutics Says New Data Shows ZORYVE Cream 0.3% Provided Measurable Improvement Of Plaque Psoriasis
Arcutis Biotherapeutics plumbs new depths on $100 mln stock offering
Brief: Arcutis Announces Pricing Of $100 Million Public Offering
Brief: Arcutis Biotherapeutics Inc Continues To Evaluate And Explore Opportunities For Further Efficiencies And Cost Savings
Brief: Arcutis Presents Positive Patient-Reported Outcome Data From The Pivotal Arrector Phase 3 Trial In Scalp And Body Psoriasis At European Academy Of Dermatology And Venereology (Eadv) Congress